P1.118. Delaying the Treatment Schedule in First-Line Chemotherapy Including ICIs for Esophageal Cancer Does Not Affect Survival Outcomes

Clicks: 1
ID: 325725
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal

Ranked #329 of 453 articles by views in diseases of the esophagus : official journal of the international society for diseases of the esophagus

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 453 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Topic Esophageal Cancer: Non-Surgical Treatment of Esophageal Cancer Background Cancer immunotherapy has dramatically changed the management of esophageal cancer. However, the impact of treatment delays on survival outcomes in first-line chemotherapy for esophageal squamous cell carcinoma (ESCC) including immune checkpoint inhibitors (ICIs) remains unclear. This study aimed to clarify the impact of treatment delays on survival outcomes in first-line chemotherapy for esophageal cancer including ICIs. Methods The study included 69 patients who underwent first-line chemotherapy using ICIs at our institution up to February 2026 and whose outcomes were known. Patients were divided into two groups: a treatment schedule delay group and a no-delay group, and a retrospective analysis of survival outcomes was performed. A treatment schedule delay was defined as a delay of 7 days or more from the scheduled start date of the second course. Results The delay group consisted of 34 patients and the no-delay group of 35. The ratios of FP (5FU + CDDP) + Pembrolizumab to FP + Nivolumab were 22:12 in the delay group and 26:9 in the non-delay group (p=0.387, chi-square test). The best response assessment was CR:PR:SD:PD ratio of 0:20:6:7 in the delay group and 0:26:5:4 in the no-delay group, with response rates of 58.8% and 74.3% (p=0.173, chi-square test) and tumor control rates of 76.5% and 88.6% (p=0.185, chi-square test), with no significant difference. The 1-year OS was 64.8% in the delay group and 60.6% in the no-delay group (p=0.851, log-rank test), and the 1-year PFS was 36.0% in the delay group and 18.1% in the no-delay group (p=0.465, log-rank test), with no significant difference observed. Conclusion In first-line chemotherapy containing ICIs for esophageal cancer, delaying the treatment schedule at the start of the second course may not affect survival outcomes. In actual clinical practice, it is appropriate to manage patients without being overly concerned about delays in the treatment schedule.
Reference Key
openalex_W7203899643 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Takeshi Toyozumi, Masaya Uesato, Akira Nakano, Y. Kurata, Tadashi Shiraishi, Nobufumi Sekino, Koichi Hayano, Yasunori Matsumoto, Yukiko Yamaguchi, Hideki Hayashi, Hisahiro Matsubara, Michihiro Maruyama
Journal diseases of the esophagus : official journal of the international society for diseases of the esophagus
Year 2026
DOI
10.1093/dote/doag077.266
URL
https://doi.org/10.1093/dote/doag077.266
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.